Administration of the intestinal specific mast cell degranulation inhibitor, doxantrazole, decreasesd gut (A) and lung (B) injury following T/HS. Data are expressed as mean ± SEM with 6–8 animals per group. In contrast, the administration of the connective tissue mast cell degranulation inhibitor, ketotifen, did not decrease gut (C) or lung (D) injury following T/HS. Data are expressed as mean ± SEM with 5–6 animals per group. *p<0.05 vs. all other groups.